The investigators hypothesize that additive effects of combined antihypertensive medications and statin in a single pill combination may better reduce progression of vascular remodeling and inhibit atherosclerosis progression. The fixed association of atorvastatin, perindopril and amlodipine under the name of Lipertance is the first fixed combination of these three groups to control the risk factors that are hypertension and dyslipidemia which can be used both in primary and secondary cardiovascular prevention .

Start Date15 Apr 2020

Sponsor / Collaborator

Yerevan State Medical University

[+1]

100 Clinical Results associated with Yerevan State Medical University

0 Patents (Medical) associated with Yerevan State Medical University

1,159

Literatures (Medical) associated with Yerevan State Medical University

01 May 2025·Journal of Autoimmunity

Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study

Article

Author: Porreca, Annamaria ; Rigante, Donato ; Bella, Saverio La ; Frenkel, Joost ; Horneff, Gerd ; Bakkaloglu, Sevcan ; Kasapcopur, Ozgur ; Simonini, Gabriele ; Sánchez-Manubens, Judith ; Legger, Elizabeth ; Bayindir, Yagmur ; Anton, Jordi ; Amarilyo, Gil ; Obici, Laura ; Jesenak, Milos ; Belder, Nuran ; Glerup, Mia ; Insalaco, Antonella ; Amaryan, Gayane ; Ozen, Seza ; Cantarini, Luca ; Brunner, Juergen ; Gattorno, Marco ; Fabio, Giovanna ; Alataki, Sofia ; Assalia, Naiera ; Alessio, Maria ; Bustaffa, Marta ; Spagnolo, Alessandra ; Ruperto, Nicolino ; Caorsi, Roberta ; Carrabba, Maria ; Gallizzi, Romina ; Breda, Luciana ; Kuemmerle-Deschner, Jasmin ; Papadopoulou-Alataki, Efimia

INTRODUCTIONThe majority of currently available data on familial Mediterranean fever (FMF) come from retrospective national or international studies.METHODSAn observational study collected data on the Eurofever international FMF cohort. Patients fulfilling genetic and clinical Eurofever criteria were considered as FMF+. Patients not fulfilling clinical and/or genetic (one VUS or benign variants or negative for MEFV variants) criteria were considered as FMF-. Data on compliance to treatment and quality of life were also recorded.RESULTSSince November 2024, 876 FMF patients (466 M, 410 F) were enrolled, with a mean follow-up of 2.9 ± 3.1 years. 730 (84 %) patients were classified as FMF+, 146 (16 %) as FMF-, with significant differences in the prevalence of clinical manifestations and treatment response between the two groups. At the last follow-up, 433 patients (50.6 %) still had some disease activity. At the last follow-up 749 (85.5 %) patients received colchicine with a relative under dosage of the drug. Anti-IL-1 treatment was reported in 133 patients (15.2 %), mostly canakinumab (117, 13.4 %). Treatment compliance was generally satisfactory, and adverse events were generally mild.CONCLUSIONSPatients with an FMF-like phenotype who lack genetic confirmation display significant differences in clinical features and duration of attacks and show a less response to treatment during their disease course in respect, and thus, should be considered as FMF-mimics and investigated for other causes. Longitudinal data provides a more detailed comprehension of the long-term burden of FMF and the impact of treatment on disease activity and patients' quality of life.

01 May 2025·Bone

Decoding fracture healing: A scoping review of mechanistic pathways derived from transcriptional analysis in murine studies

Review

Author: Nafisi, Nazanin ; Mirzamohammadi, Hamid ; Nazarian, Ara ; Manoukian, David ; Klujian, Arthur ; Khak, Mohammad ; Mirzamohammadi, Fatemeh ; Shariyate, Mohammad Javad ; Rostami, Mahboubeh R ; Velasquez, Maria V ; Cummiskey, Tom ; Razavi, Ahmad Hedayatzadeh

Fracture healing is a complex biological process involving orchestrated interactions among cells, growth factors, and transcriptional pathways. Despite significant advancements in understanding bone repair, non-union and delayed healing remain prevalent, especially in patients with comorbidities such as aging, diabetes, or substance use. Murine models serve as a cornerstone in fracture healing research, offering genetic manipulability, cost-effectiveness, and biological relevance to humans. This scoping review consolidates findings from studies conducted between 2010 and 2024, focusing on mechanistic pathways derived from transcriptional analysis in secondary bone healing as identified through bulk RNA sequencing of murine models. Key mechanistic pathways were categorized and analyzed across the distinct phases of fracture healing-reactive, reparative, and remodeling-highlighting their unique roles in inflammation, ECM remodeling, cell proliferation, and tissue mineralization. The most recurrent mechanistic pathways included ECM-receptor interaction, focal adhesion, and signaling mechanisms such as MAPK and TGF-beta. Variability in methodologies and limited overlap among studies underscore the need for standardized protocols in RNA sequencing analysis. Additionally, comparisons across long bone fractures, hole defects, and craniofacial bone healing revealed shared molecular mechanisms alongside unique challenges, particularly in craniofacial models. This scoping review underscores the promise of integrating systems biology approaches with transcriptomic data to elucidate the intricate regulatory networks governing fracture repair. Addressing the identified gaps in early-phase healing and harmonizing research methodologies will advance therapeutic strategies to reduce non-union rates and improve clinical outcomes.

23 Apr 2025·European Heart Journal: Acute Cardiovascular Care

The impact of total ischemic time on in-hospital mortality and complications in patients with ST-elevation myocardial infarction

Author: Hayrapetyan, H G ; Arakelyan, I A ; Petrosyan, H H ; Muradyan, F I ; Hayrapetyan, L H ; Ter-Grigoryan, V R

AbstractBackgroundThe central treatment for acute ST-elevation myocardial infarction (STEMI) is myocardial reperfusion with primary percutaneous coronary intervention (PCI), which must be done quickly. The total ischemic time (TIT), measured from symptom onset to the provision of reperfusion therapy, is critical for the prognosis of STEMI patients.Objectivethe purpose of this study was to examine the impact of TIT on in-hospital complications in patients with acute STEMI.MethodsThe study included 971 patients. The patients were split into four groups based on the TIT value: Group 1 (<3 hours), Group 2 (≥ 3 and < 6 hours), Group 3 (≥6 hours and < 9 hours), and Group 4 (≥ 9 and < 12 hours).The incidence rates of complications including atrial fibrillation (AF), ventricular tachycardia (VT), ventricular fibrillation (VF), high-degree atrioventricular (AV) block, in-hospital pneumonia, and in-hospital death were compared across these groups. Chi-square tests were employed to assess statistical significance.ResultsThe analysis revealed a statistically significant increase in the incidence of AF: Group 1 5.0%, Group 2 7.5%, Group 3 10.0% and Group 4 12.5% (p = 0.041), VF Group 1 2.5%, Group 2 3.5%, Group 3 5% and Group 4 7% (p = 0.048), in-hospital pneumonia Group 1 4.0%, Group 2 5.5%, Group 3 7.0% and Group 4 9.0% (p = 0.029), and in-hospital death Group 1 2.0%, Group 2 3.0%, Group 3 4.5% and Group 4 6.5% (p = 0.031) with longer TIT. No significant associations were found between TIT and the incidence of VT: Group 1 3.0%, Group 2 4.5%, Group 3 6.0%, Group 4 8.0% (p = 0.105), and high degree AV block Group 1 1.0%, Group 2 2.0%, Group 3 3.0% and Group 4 4.0% (p = 0.129). Patients in Group 4 had significantly higher AF rates than those in Groups 1 and 2( p < 0.05). Group 4 exhibited a significantly higher incidence of VF than Group 1( p < 0.05). The incidence of in-hospital pneumonia was significantly higher in Group 4 compared to Groups 1 and 2( p < 0.05). In-hospital mortality rates were significantly higher in Group 4 compared to Groups 1 and 2 ( p < 0.05).ConclusionPatients with longer TIT are at higher risk for certain complications compared to those with shorter ischemic times. Prolonged TIT is significantly associated with higher rates of AF, VF, in-hospital pneumonia, and in-hospital mortality. These findings underline the importance of minimizing ischemic time to improve patient outcomes.

100 Deals associated with Yerevan State Medical University

100 Translational Medicine associated with Yerevan State Medical University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 19 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Yerevan State Medical University

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 19 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing